Dr. Matthew Galsky, MD

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Tufts University

  Medical School, 1998

• Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer, 2015-11-04

• Emerging role of immunotherapy in urothelial carcinoma - immunobiology/biomarkers, 2016-11-09

• Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis, 2012-12-08

• A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent, 2015-11-04

• Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms, 2022-11-03

• Tumor Downstaging as an Intermediate Endpoint to Assess the Activity of Neoadjuvant Systemic Therapy in Patients With Muscle-Invasive Bladder Cancer, 2019-05-31

• The role of GATA2 in lethal prostate cancer aggressiveness, 2016-11-22

• Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer, 2018-09-13

• Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials, 2012-11-26

• Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors, 2014-07-15

• Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect, 2019-07-11

• Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer, 2019-07-01

• Summary of the 6th annual bladder cancer think tank: New directions in urologic research, 2012-01-31

• Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study, 2020-07-22

• Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer, 2022-11-04

• A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors, 2021-01-07

• Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery, 2023-01-09

• SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer, 2018-09-20

• Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma, 2017-09-28

• Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma, 2016-12-23

• Phase II Study of Neoadjuvant Chemotherapy with Docetaxel and Bevacizumab in Patients with High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials Consortium Trial, 2012-01-26

• Metabolic disease and adverse events from immune checkpoint inhibitors, 2021-05-10

• Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets, 2021-09-22

• Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing, 2021-04-09

• Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial, 2022-02-12

• Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors, 2019-12-12

• Clinical trial awareness: Changes over time and sociodemographic disparities, 2015-02-10

• TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer, 2020-07-12

• Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward, 2014-07-25

• Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival, 2016-12-20

• Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials, 2018-09-07

• Selective PP2A enhancement through biased heterotrimer stabilization, 2020-04-20

• Unfavourable cancer specific survival after neoadjuvant chemotherapy and radical cystectomy in bladder cancer patients with squamous-cell variant: A multi-institutional study, 2020-02-08

• Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors, 2020-06-18

• Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors, 2017-08-24

• Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers, 2020-05-21

• All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase, 2015-11-14

• Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database, 2019-07-13

• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial, 2016-03-04

• Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy, 2022-10-05

• Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis, 2013-07-13

• Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR, 2018-07-03

• The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic, 2021-09-27

• Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study, 2023-03-10

• Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers, 2019-01-31

• Small Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer, 2018-01-22

• Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database, 2018-11-19

• The Khorana score in predicting venous thromboembolism for metastatic urothelial carcinoma and variant histology patients treated with chemotherapy, 2016-09-16

• Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States, 2012-05-24

• Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-?B Ligand Inhibitors in Patients with Advanced Prostate Cancer, 2013-05-13

• Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes, 2020-12-23

• Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population, 2017-11-01

• NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer, 2022-09-12

• Metabolic complications with the use of mTOR inhibitors for cancer therapy, 2013-05-16

• Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations, 2018-05-30

• Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study, 2020-01-23

• Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial, 2022-03-11

• Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?, 2021-10-13

• EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer, 2018-08-29

• Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma, 2013-09-28

• Multicenter Phase 2 Trial of the Hsp-90 Inhibitor, IPI-504 (retaspimycin hydrochloride), in Patients with Castration-Resistant Prostate Cancer, 2011-07-18

• Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import, 2018-08-09

• Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer, 2015-06-15

• Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer, 2016-10-20

• Analysis of the Correlation between Endorectal MRI Response to Neoadjuvant Chemotherapy and Biochemical Recurrence in Patients with High-Risk Localized Prostate Cancer, 2013-05-28

• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma, 2017-08-15

• Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association With Comprehensive Genomic Profiling and/or Cell-Free DNA Results, 2020-03-24

• The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies, 2020-10-07

• Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel, 2015-01-20

• Chemotherapy regimen is associated with venous thromboembolism risk in urothelial tract cancer patients, 2019-02-19

• A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles, 2020-02-28

• Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition, 2016-05-10